Company profile
GRIFOLS SA
NASDAQ:GRFSBiotechnology: Pharmaceutical Preparations
Drug pipeline (23)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 | approved | — | 0 | — |
| ALBUTEIN | approved | — | 0 | — |
| ALPHANATE | approved | — | 0 | — |
| ALPHANINE, ALPHANINE HP, ALPHANINE SD | approved | — | 0 | — |
| BAYGAM, GAMASTAN S/D | approved | — | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (75)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07582432 | phase3 | recruiting | 2026-05-11 | 2028-08-31 | Grifols Biologicals, LLC | A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma |
| NCT00418483 | phase1 | completed | 2007-03-01 | 2010-04-01 | Grifols Therapeutics LLC | A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion |
| NCT07555483 | phase3 | recruiting | 2026-05-05 | 2027-09-30 | Grifols Therapeutics LLC | A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) |
| NCT01014975 | phase1_2 | completed | 2009-11-01 | 2013-11-01 | Grifols Therapeutics LLC | A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients |
| NCT01222117 | phase2 | completed | 2010-12-01 | 2015-12-01 | Grifols Therapeutics LLC | A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion |
FDA applications (22)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125833 | 2025-12-16 | BLA | GRIFOLS THERAPEUTICS LLC | |||||
Loading… | ||||||||
| BLA 125683 | 2019-07-03 | BLA | GRIFOLS THERAPEUTICS LLC | |||||
Loading… | ||||||||
| BLA 125640 | 2017-11-01 | BLA | INSTITUTO GRIFOLS, S.A. | |||||
Loading… | ||||||||
| ANDA 207956 | 2017-05-25 | ANDA | LABORATORIOS GRIFOLS SA | |||||
Loading… | ||||||||
| BLA 125077 | 2003-12-15 | BLA | INSTITUTO GRIFOLS, S.A. | |||||
Loading… | ||||||||